TP53 and colorectal carcinoma: TP53 mutation, as reported, determines many biological behaviors of CRC, such as lymphatic and vascular invasion, chemoresistance, and the prognosis of patients (Russo et al., 2005; Iacopetta et al., 2006; Li et al., 2015).